Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > News response
View:
Post by Pareto8020 on Jun 18, 2024 11:22am

News response

Seems to be a tepid response to the write-up with a paltry 40 shares traded so far.

This is a "show me the money" stock now and until they do that it likely isn't going to see a tremendous amount of action.

If they could announce some AbbVie milestones or royalties on the near horizon that would be an ideal catalyst to jolt this back to life.
Comment by lscfa on Jun 18, 2024 11:54am
The full report:   does not say SBM is a publicly traded co,    does not provide a valuation on SBM,     does not provide any timing other than GPM to lauch in 2025
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities